Metreleptin for treating lipodystrophy
KEYWORDS: metreleptin, lipodystrophy, treatment, people, company, committee, clinical, liver, experts, partial, section, evidence, noted, partial lipodystrophy, baseline

Impact of the technology beyond direct health benefits and on the delivery of the specialised service 4.31 The committee discussed the effects of metreleptin beyond its direct health benefits. It understood from patient experts that children with hyperphagia need considerable carer support, which can have a significant effect on families. It noted that the treatment may have benefits beyond health in children and young people with generalised lipodystrophy. They may account for a minority of the patient population, but the treatment may have important implications for their schooling, interactions with their parents, and social life. This could lead to profound psychosocial benefits for individuals. In adults, hyperphagia and fatigue can compromise their social and professional lives. The committee acknowledged that lipodystrophy affects patients beyond direct health benefits but that quantifying this was difficult. However, it concluded that the effects are qualitatively accounted for in its decision making. 4.32 The committee noted that lipodystrophy is managed in an established specialist centre at Addenbrooke's Hospital in Cambridge. This means that additional infrastructure or staff training is not expected to be needed to introduce metreleptin in England. 4.33 The committee noted that the population for which metreleptin is indicated includes children and young
